研究文章
基于第二阶段试验的美法仑的强度来调节移植T-Replete HLA-Haploidentical外周血干细胞与环磷酰胺血液恶性肿瘤患者具有重要的意义
|
|
价值 |
流感/梅尔 |
流感/ Cy /创伤性脑损伤 |
|
|
| N |
25 |
61年 |
|
| 年龄、中值(范围) |
57 (68) |
61 (75) |
0.10 |
| 男性性 |
11 (44%) |
32 (52%) |
0.64 |
| 诊断 |
|
|
0.08 |
| AML |
11 (44%) |
13 (21%) |
|
| 所有 |
4 (16%) |
4 (7%) |
|
| MDS /议员/ CML |
6 (24%) |
14 (23%) |
|
| NHL /慢性淋巴细胞白血病/高清 |
3 (12%) |
24 (39%) |
|
| 纤毛运动 |
1 (4%) |
2 (3%) |
|
| 其他 |
0 (0%) |
4 (8%) |
|
| 细胞来源 |
|
|
< 0.001 |
| PBSC |
25 (100%) |
37 (61%) |
|
| BM |
0 (0%) |
24 (39%) |
|
| 病人巨细胞病毒 |
|
|
0.38 |
| 积极的 |
18 (72%) |
50 (82%) |
|
| 负 |
7 (28%) |
11 (18%) |
|
| 土著居民的兼容性 |
|
|
0.32 |
| 兼容的 |
16 (64%) |
33 (54%) |
|
| 不兼容的小 |
2 (8%) |
15 (25%) |
|
| 不兼容的轻度和重度 |
1 (4%) |
2 (3%) |
|
| 不兼容的主要 |
6 (24%) |
11 (18%) |
|
| DRI |
|
|
0.06 |
| 低 |
1 (4%) |
7 (12%) |
|
| 中间 |
13 (52%) |
27 (45%) |
|
| 高/非常高 |
11 (44%) |
23 (38%) |
|
| CMl |
|
|
0.09 |
| 1 - 3 |
11 (44%) |
39 (64%) |
|
| 4 - 8 |
14 (56%) |
22 (36%) |
|
| 女性捐赠者男性收件人 |
4 (16%) |
8 (13%) |
0.74 |
|
|
